Breaking News Instant updates and real-time market news.

MRK

Merck

$72.01

0.25 (0.35%)

11:25
10/03/18
10/03
11:25
10/03/18
11:25

Economic Club of New York hold a luncheon meeting

Luncheon Meeting with Merck CEO Frazier will be held in New York on October 3 at 11:30 am.

  • 03

    Oct

  • 03

    Oct

  • 17

    Oct

  • 23

    Oct

  • 29

    Oct

  • 11

    Jan

  • 16

    Feb

MRK Merck
$72.01

0.25 (0.35%)

06/14/18
MSCO
06/14/18
NO CHANGE
Target $68
MSCO
Overweight
Merck Q2 estimates lowered below consensus at Morgan Stanley
Morgan Stanley analyst David Risinger cut his Q2 revenue estimate for Merck by 1% to $10.1B, which he notes is below the consensus view of $10.3B, and lowered his Q2 EPS estimate by 6% to 97c. This is below the consensus view of $1.03, which he argues "needs to come down." The two key drivers were lowering his estimates for Keytruda in the U.S. due to a more gradual ramp in first-line lung cancer patients and the negative impact of hedging, which he sees being similar to, but less pronounced, than in Q1. He lowered his full-year EPS view by only 1%, however, which puts it 2% below consensus. Risinger keeps an Overweight rating and $68 price target on Merck shares.
06/28/18
WELS
06/28/18
NO CHANGE
WELS
Wells says Amazon deal, Walgreens results have negative read for drug pricing
After Amazon (AMZN) agreed to acquire online pharmacy PillPack, reportedly for $1B, Wells Fargo analyst David Maris noted that he has long stated that Amazon would enter the pharmacy business and warned about the risk to drug pricing in such a scenario. Maris also noted that Walgreens (WBA) reported its U.S. retail pharmacy comparable store sales fell 1.2% in Q3, adding that retailers tend to push drugmakers on price when they feel pressure and the read-through from its report may be negative for drug pricing. Publicly traded large-cap drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
07/11/18
WELS
07/11/18
NO CHANGE
WELS
Drug stocks may not react favorably to Pfizer price rollback, Trump tweets, says Wells Fargo
Wells Fargo analyst David Maris notes that there was widespread media coverage of drug price increases taken recently by several large cap drug companies, with President Trump criticizing Pfizer (PFE) for taking these price increases. On Tuesday, Pfizer confirmed it was rolling back its July drug price increases following a conversation with President Trump, he adds. Maris believes that drug stocks will not react favorably to this news, given the chilling effect this will likely have on others looking to take price increases. Nonetheless, the analyst points out that the price increases taken in July are only a small number of increases taken over the past year or several years, so the impact of the rollback to the healthcare system is insignificant in the big picture. Other publicly traded companies in the space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Roche (RHHBY) and Sanofi (SNY).
08/23/18
MSCO
08/23/18
NO CHANGE
Target $74
MSCO
Overweight
Merck price target raised to $74 from $68 at Morgan Stanley
Morgan Stanley analyst David Risinger maintained an Overweight rating on Merck and raised his price target to $74 from $68, citing his expectation for operating leverage to become more visible in 2019 and pipeline progress to improve perception about prospects in the face of Januvia generics in January 2023. Looking ahead, Risinger projects Merck's 5-year CAGR from 2018-2023 for revenue growth of 3% and EPS growth of 8%. Risinger says he believes the primary driver of major pharma stock performance in recent months is "defensive rotation." Looking ahead, the analyst says to watch for U.S. pricing perception drivers in the coming months that could impact pharma stock performance, including potential additional HHS action on drug rebates, November election results and manufacturer communication and action on U.S. list prices by early January.

TODAY'S FREE FLY STORIES

CHKP

Check Point

$110.75

-1.34 (-1.20%)

07:23
10/19/18
10/19
07:23
10/19/18
07:23
Initiation
Check Point initiated  »

Check Point initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 10

    Dec

F

Ford

$8.51

-0.255 (-2.91%)

, GM

General Motors

$31.08

-0.84 (-2.63%)

07:22
10/19/18
10/19
07:22
10/19/18
07:22
Downgrade
Ford, General Motors rating change  »

Morgan Stanley downgrades…

F

Ford

$8.51

-0.255 (-2.91%)

GM

General Motors

$31.08

-0.84 (-2.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

  • 13

    Dec

07:20
10/19/18
10/19
07:20
10/19/18
07:20
General news
FX Update: The Dollar has been choppy »

FX Update: The Dollar has…

OKE

Oneok

$66.94

-0.07 (-0.10%)

07:19
10/19/18
10/19
07:19
10/19/18
07:19
Upgrade
Oneok rating change  »

Oneok upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

GBT

Global Blood Therapeutics

$38.15

2.37 (6.62%)

07:19
10/19/18
10/19
07:19
10/19/18
07:19
Recommendations
Global Blood Therapeutics analyst commentary  »

FDA may consider…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Dec

YARIY

Yara

$0.00

(0.00%)

07:17
10/19/18
10/19
07:17
10/19/18
07:17
Upgrade
Yara rating change  »

Yara upgraded to Buy from…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VOLVY

Volvo

$0.00

(0.00%)

07:17
10/19/18
10/19
07:17
10/19/18
07:17
Periodicals
Volvo CEO says doesn't expect fine from emissions probe, Bloomberg says »

Volvo CEO says emissions…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ASB

Associated Banc-Corp

07:17
10/19/18
10/19
07:17
10/19/18
07:17
Downgrade
Associated Banc-Corp rating change  »

Associated Banc-Corp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

AXP

American Express

$102.86

-1.53 (-1.47%)

07:16
10/19/18
10/19
07:16
10/19/18
07:16
Recommendations
American Express analyst commentary  »

Oppenheimer remains a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Nov

ECYT

Endocyte

$23.40

7.85 (50.48%)

, NVS

Novartis

$86.24

0.9 (1.05%)

07:16
10/19/18
10/19
07:16
10/19/18
07:16
Downgrade
Endocyte, Novartis rating change  »

Endocyte downgraded to…

ECYT

Endocyte

$23.40

7.85 (50.48%)

NVS

Novartis

$86.24

0.9 (1.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 19

    Oct

  • 07

    Nov

07:15
10/19/18
10/19
07:15
10/19/18
07:15
General news
Oil Action: Front-month WTI crude prices are up 0.7% »

Oil Action: Front-month…

AVXL

Anavex

$2.47

0.015 (0.61%)

07:14
10/19/18
10/19
07:14
10/19/18
07:14
Hot Stocks
Anavex receives FDA approval of IND for Phase 2 trial of Anavex 2-73 »

Anavex announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HOG

Harley-Davidson

$40.37

-1.29 (-3.10%)

07:14
10/19/18
10/19
07:14
10/19/18
07:14
Downgrade
Harley-Davidson rating change  »

Harley-Davidson…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

WMT

Walmart

$96.19

-0.37 (-0.38%)

07:13
10/19/18
10/19
07:13
10/19/18
07:13
Recommendations
Walmart analyst commentary  »

Oppenheimer more…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Oct

  • 15

    Nov

CTSH

Cognizant

$73.60

-0.4 (-0.54%)

07:13
10/19/18
10/19
07:13
10/19/18
07:13
Recommendations
Cognizant analyst commentary  »

Cognizant risk/reward…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 22

    Oct

  • 24

    Oct

  • 30

    Oct

  • 02

    Nov

  • 16

    Nov

QSR

Restaurant Brands

$57.16

0.08 (0.14%)

07:12
10/19/18
10/19
07:12
10/19/18
07:12
Recommendations
Restaurant Brands analyst commentary  »

Restaurant Brands'…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

IBKC

Iberiabank

$75.27

-2.65 (-3.40%)

07:11
10/19/18
10/19
07:11
10/19/18
07:11
Hot Stocks
Iberiabank sees FY19 average earning assets $28.6B-$28.9B »

Sees FY19 net interest…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

VLRX

Valeritas

$1.22

-0.04 (-3.17%)

07:10
10/19/18
10/19
07:10
10/19/18
07:10
Hot Stocks
Valeritas announces launch of V-Go in Italy »

Valeritas announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Oct

PGTI

PGT Innovations

$21.93

-0.33 (-1.48%)

07:10
10/19/18
10/19
07:10
10/19/18
07:10
Initiation
PGT Innovations initiated  »

PGT Innovations initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

07:10
10/19/18
10/19
07:10
10/19/18
07:10
General news
Canada retail sales preview »

Canada retail sales…

07:10
10/19/18
10/19
07:10
10/19/18
07:10
General news
Canada CPI preview »

Canada CPI preview:…

MYGN

Myriad Genetics

$44.61

0.18 (0.41%)

07:09
10/19/18
10/19
07:09
10/19/18
07:09
Hot Stocks
Myriad Genetics announces new data on Vectra test for RA treatment »

Myriad Genetics announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 06

    Nov

KBAL

Kimball International

$15.93

-0.27 (-1.67%)

07:08
10/19/18
10/19
07:08
10/19/18
07:08
Hot Stocks
Kimball International to acquire David Edward for $4.85M »

Kimball, a subsidiary of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

VFC

VF Corp.

$87.07

-2.22 (-2.49%)

07:08
10/19/18
10/19
07:08
10/19/18
07:08
Hot Stocks
VF Corp. CEO says Q2 results 'were strong driven by our core brands' »

"VF's second…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

PYPL

PayPal

$77.50

-2.61 (-3.26%)

, V

Visa

$139.32

-3.1 (-2.18%)

07:08
10/19/18
10/19
07:08
10/19/18
07:08
Recommendations
PayPal, Visa, MasterCard analyst commentary  »

PayPal price target…

PYPL

PayPal

$77.50

-2.61 (-3.26%)

V

Visa

$139.32

-3.1 (-2.18%)

MA

MasterCard

$203.81

-3.58 (-1.73%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 22

    Oct

  • 24

    Oct

  • 24

    Oct

  • 30

    Oct

  • 13

    Nov

  • 13

    Nov

  • 26

    Nov

  • 29

    Jan

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.